{rfName}
Ex

Indexed in

License and Use

Icono OpenAccess

Citations

20

Altmetrics

Analysis of institutional authors

Carbonell, CAuthorBodro MAuthorDe La Mora MAuthorGarcia-Vidal CAuthorGonzalez-Cordon AAuthorHernandez-Meneses MAuthorInciarte AAuthorLaguno MAuthorLeal LAuthorMorata LAuthorPuerta-Alcalde PAuthorRico VAuthorSolà MAuthorTorres BAuthorSoriano ACorresponding AuthorGarcia FAuthor

Share

September 21, 2021
Publications
>
Article
Sí

Experience with the use of siltuximab in patients with SARS-CoV-2 infection

Publicated to: Revista Espanola De Quimioterapia. 34 (4): 337-341 - 2021-08-01 34(4), DOI: 10.37201/req/045.2021

Authors:

Meira, Fernanda; Albiach, Laia; Carbonell, Cristina; Martin-Oterino, Jose-Angel; Martin-Ordiales, Mercedes; Linares, Laura; Macaya, Irene; Aguero, Daiana; Ambrosioni, Juan; Bodro, Marta; Cardozo, Celia; Chumbita, Mariana; De la Mora, Lorena; Garcia-Pouton, Nicole; Garcia-Vidal, Carolina; Gonzalez-Cordon, Ana; Hernandez-Meneses, Marta; Inciarte, Alexy; Laguno, Montserrat; Leal, Lorna; Morata, Laura; Puerta-Alcalde, Pedro; Rico, Veronica; Letona, Laura; Cozar-Llisto, Alberto; Duenas, Gerard; Sola, Montserrat; Torres, Berta; Rojas, Jhon; Moreno, Antonio; Moreno-Garcia, Estela; Torres, Manuel; Martinez, Jose A; Soriano, Alex; Garcia, Felipe
[+]

Affiliations

Alex Soriano, Department of Infectious Diseases, Hospital Clínic of Barcelona. Carrer de Villarroel 170, 08036, Barcelona, Spain. asoriano@clinic.cat. - Author
Hosp Clin Barcelona, Dept Infect Dis, Villarroel 170, Barcelona 08036, Spain - Author
Univ Hosp Salamanca IBSAL, Dept Internal Med, Salamanca, Spain - Author
See more

Abstract

The study aims to describe characteristics and clinical outcome of patients with SARS-CoV-2 infection that received siltuximab according to a protocol that aimed to early block the activity of IL-6 to avoid the progression of the inflammatory flare.Retrospective review of the first 31 patients with SARS-CoV-2 treated with siltuximab, in Hospital Clinic of Barcelona or Hospital Universitario Salamanca, from March to April 2020 with positive polymerase-chain reaction (PCR) from a nasopharyngeal swab.The cohort included 31 cases that received siltuximab with a median (IQR) age of 62 (56-71) and 71% were males. The most frequent comorbidity was hypertension (48%). The median dose of siltuximab was 800 mg ranging between 785 and 900 mg. 7 patients received siltuximab as a salvage therapy after one dose of tocilizumab. At the end of the study, a total of 26 (83.9) patients had been discharged alive and the mortality rate was 16.1% but only 1 out of 24 that received siltuximab as a first line option (4%).Siltuximab is a well-tolerated alternative to tocilizumab when administered as a first line option in patients with COVID-19 pneumonia within the first 10 days from symptoms onset and high C-reactive protein.©The Author 2021. Published by Sociedad Española de Quimioterapia. This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0)(https://creativecommons.org/licenses/by-nc/4.0/).
[+]

Keywords

covid-19 mortalitysiltuximabAgedAntibodies, monoclonalAntibodies, monoclonal, humanizedC-reactive proteinCovid-19Covid-19 drug treatmentCytokine release syndromeDisease progressionFemaleHumansHypertensionIl-6Il6 protein, humanInterleukin-6MaleMiddle agedMortalityRetrospective studiesSalvage therapySiltuximabTocilizumabTreatment outcome

Quality index

Bibliometric impact. Analysis of the contribution and dissemination channel

The work has been published in the journal Revista Espanola De Quimioterapia, and although the journal is classified in the quartile Q3 (Agencia WoS (JCR)), its regional focus and specialization in Pharmacology & Pharmacy, give it significant recognition in a specific niche of scientific knowledge at an international level.

Independientemente del impacto esperado determinado por el canal de difusión, es importante destacar el impacto real observado de la propia aportación.

Según las diferentes agencias de indexación, el número de citas acumuladas por esta publicación hasta la fecha 2026-01-31:

  • WoS: 6
  • Scopus: 7
  • Europe PMC: 5
[+]

Impact and social visibility

From the perspective of influence or social adoption, and based on metrics associated with mentions and interactions provided by agencies specializing in calculating the so-called "Alternative or Social Metrics," we can highlight as of 2026-01-31:

  • The use of this contribution in bookmarks, code forks, additions to favorite lists for recurrent reading, as well as general views, indicates that someone is using the publication as a basis for their current work. This may be a notable indicator of future more formal and academic citations. This claim is supported by the result of the "Capture" indicator, which yields a total of: 40 (PlumX).

It is essential to present evidence supporting full alignment with institutional principles and guidelines on Open Science and the Conservation and Dissemination of Intellectual Heritage. A clear example of this is:

  • The work has been submitted to a journal whose editorial policy allows open Open Access publication.
  • Additionally, the work has been submitted to a journal classified as Diamond in relation to this type of editorial policy.
[+]

Leadership analysis of institutional authors

There is a significant leadership presence as some of the institution’s authors appear as the first or last signer, detailed as follows: Last Author (Garcia Alcaide, Felipe).

the author responsible for correspondence tasks has been Soriano Viladomiu, Alex.

[+]

Awards linked to the item

This research is part of an activity that has received funding from EUSA Pharma for the present study, the research group has received a grant from crowdfunding organized by Hospital Clinic and IDIBAPS. No funding bodies had any role in study design, data collection and analysis, decision to publish or preparation of the manuscript.
[+]